• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Solana Company

    3/31/26 9:14:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HSDT alert in real time by email
    S-8 1 tm269715d5_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 31, 2026

    Registration No. 333-

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

    Solana Company
    (Exact name of registrant as specified in its charter)

     

     

    Delaware   36-4787690
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
       
    642 Newtown Yardley Road, Suite 100
    Newtown, Pennsylvania
      18940
    (Address of principal executive offices)   (Zip code)

     

    2022 Equity Incentive Plan

    (Full title of the plan)

     

    Dane C. Andreeff
    President and Chief Executive Officer
    Solana Company
    642 Newtown Yardley Road, Suite 100
    Newtown, Pennsylvania 18940
    (215) 944-6100
    (Name, address, and telephone number, including area code, of agent for service)

     

     

    Copy to:

     

    Jason L. Kent

    Peter M. Byrne

    Cooley LLP

    55 Hudson Yards

    New York, NY 10001-2157

    Telephone: (212) 470-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed by Solana Company (the “Registrant,” “we,” “us,” or “our”), for the purpose of registering an aggregate of 11,965,869 additional shares of Class A common stock, par value $0.001 per share (the “Common Stock”), under the Registrant’s 2022 Equity Incentive Plan, as amended (the “2022 Plan”), including (i) 7,965,869 shares of Common Stock pursuant to an “evergreen provision” and (ii) 4,000,000 shares of Common Stock under the Third Amendment to the 2022 Plan, which was approved by the Registrant’s board of directors on September 25, 2025 and by the Registrant’s stockholders at the Registrant’s special meeting of stockholders on October 30, 2025.

     

    The Registrant previously registered shares of Common Stock for issuance under the 2022 Plan pursuant to Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the “Commission”) on May 31, 2022 (File No. 333-265324), January 19, 2023 (File No. 333-269305), July 24, 2024 (File No. 333-280978), March 25, 2025 (File No. 333-286100) and July 10, 2025 (File No. 333-288608) (the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference, except that the provisions contained in Part II of such Prior Registration Statements are modified or supplemented, as the case may be, as set forth in this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

     

    a) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Commission on March 31, 2026; 

     

    b) the Registrant’s Current Report on Form 8-K filed with the SEC on February 20, 2026; and
    c) the description of the Registrant’s Common Stock contained in the Registrant’s Form 8-A (File No. 001-38445) filed with the Commission on April 4, 2018, as amended by the description of the Common Stock contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, and as further amended by any subsequent amendment or report filed for the purpose of updating such description.

     

    In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

     

    Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    INDEX TO EXHIBITS

     

    Exhibit
    Number
      Description
         
    4.1   Certificate of Conversion filed with the Delaware Secretary of State on July 18, 2018 (incorporated by reference to Exhibit 3.1 to the Form 10-Q filed August 9, 2018)
         
    4.2   Certificate of Incorporation, as corrected (incorporated by reference to Exhibit 3.1 to the Form 8-K filed October 30, 2018)
         
    4.3   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on December 31, 2020)
         
    4.4   Corrected Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed August 16, 2023)
         
    4.5   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed April 30, 2025)
         
    4.6   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8 K filed on June 27, 2025)
         
    4.7   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed September 18, 2025)
         
    4.8   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Form 8-K filed September 29, 2025)
         
    4.9   Third Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Form 8-K filed September 29, 2025)
         
    5.1*   Opinion of Cooley LLP
         
    23.1*   Consent of CBIZ CPAs P.C., independent registered public accounting firm for the year ended December 31, 2025
         
    23.2*   Consent of Baker Tilly US, LLP, independent registered public accounting firm for the year ended December 31, 2024
         
    23.3*   Consent of Cooley LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)
         
    24.1*   Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
         
    99.1   2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed February 18, 2022)
         
    99.2   Amendment to the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K filed June 28, 2024)
         
    99.3   Second Amendment to the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 4.11 to the Registration Statement on Form S-8 filed July 10, 2025)
         
    99.4   Third Amendment to the 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.13.4 to the Annual Report on Form 10-K filed on March 31, 2026) 
         
    99.5   2022 Equity Incentive Plan Form of Stock Option Agreement (incorporated by reference to Exhibit 10.3 to the Form 8-K filed February 18, 2022)
         
    107*   Filing Fee Table

     

     

    *Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, hereunto duly authorized, in the City of Newtown, State of Pennsylvania, on March 31, 2026.

     

     Solana Company

     

    By:/s/ Dane C. Andreeff
      Dane C. Andreeff
      President, Chief Executive Officer and Director

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dane C. Andreeff and Jeffrey S. Mathiesen as his or her true and lawful attorneys-in-fact and agents with full power of substitution, severally, for him in any and all capacities, to sign the Registration Statement on Form S-8 of Solana Company, and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    SIGNATURE   TITLE   DATE
             

    /s/ Dane C. Andreeff

    Dane C. Andreeff

      President and Chief Executive Officer
    (Principal Executive Officer) and Director
      March 31, 2026
             

    /s/ Jeffrey S. Mathiesen

    Jeffrey S. Mathiesen

      Chief Financial Officer
    (Principal Financial Officer and Principal Accounting Officer), Treasurer and Secretary
      March 31, 2026
             

    /s/ Joseph Chee

    Joseph Chee

      Executive Chairman and Director   March 31, 2026
             

    /s/ Paul Buckman

    Paul Buckman

      Director   March 31, 2026
             

    /s/ Blane Walter

    Blane Walter

      Director   March 31, 2026
             

    /s/ Sherrie Perkins

    Sherrie Perkins

      Director   March 31, 2026
             

    /s/ Edward M. Straw

    Edward M. Straw

      Director   March 31, 2026
             

    /s/ Cosmo Jiang

    Cosmo Jiang

      Director   March 31, 2026

     

     

     

    Get the next $HSDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSDT

    DatePrice TargetRatingAnalyst
    11/15/2021Outperform → Market Perform
    Noble Capital Markets
    More analyst ratings

    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Tech downgraded by Noble Capital Markets

    Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform

    11/15/21 10:55:44 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Noble Capital Markets initiated coverage on Helius Medical with a new price target

    Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00

    3/24/21 8:02:45 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

    LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy

    2/12/21 8:21:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jiang Cosmo Yi

    3 - Solana Co (0001610853) (Issuer)

    10/31/25 6:51:45 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    7/3/25 8:00:26 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

    4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    2/15/24 4:06:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/15/23 7:00:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

    4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    12/4/23 8:30:12 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    SEC Filings

    View All

    SEC Form S-8 filed by Solana Company

    S-8 - Solana Co (0001610853) (Filer)

    3/31/26 9:14:57 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form POS AM filed by Solana Company

    POS AM - Solana Co (0001610853) (Filer)

    3/31/26 9:12:31 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form POS AM filed by Solana Company

    POS AM - Solana Co (0001610853) (Filer)

    3/31/26 9:10:14 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026

    NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its fourth quarter and full year operating results on Monday, March 30, 2026, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Monday, March 30, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived unde

    3/24/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana

    Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assetsExpansion planned to enable Solana Company to capture more value by eliminating external costs and providing compliant infrastructure for regulated institutionsStrategic buildout designed to address needs of market makers, high-frequency traders, exchanges, and traditional finance partners across the Solana ecosystem NEWTOWN, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT or the "Company") today rolled out a strategic roadmap to invest in a new low-latency cluster in Asia Pacific to drive staking and v

    2/23/26 9:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Solana Company Executive Chairman's Message: October 20th, 2025

    NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ:HSDT) released the following letter from the Executive Chairman: We are excited to enter the next phase of our lifecycle with a strong capital base and expanded accessibility for investors. This week will be remembered as a foundational moment for Solana Company (NASDAQ:HSDT). We have made the deliberate choice to move forward with our scheduled registration for resale of the shares purchased by investors in the recent private placement rather than delay it. Whereas some of our peers have decided to postpone it at the first sign of market volatility, we want to explain why we made this decision and why we feel

    10/20/25 10:18:15 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

    -Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. "The recent reimbursement approvals from two major

    6/11/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

    NEWTOWN, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced it will highlight the results of a new study confirming the therapeutic regimen and sustained efficacy of its Portable Neuromodulation Stimulator (PoNS®) device for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. The event runs from May 28-31 at the Phoenix Convention Center in Phoenix. Deborah Backus, PT, Ph.D., FACRM – Vice President of Research and Innovation at Atlanta's Shepherd Center, one of six sit

    5/20/25 7:00:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    2/13/24 7:09:07 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HSDT
    Financials

    Live finance-specific insights

    View All

    Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results

    NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year Recent Business Updates Generated $5.1 million in staking rewards in the fourth quarter of 2025 and $5.5 million for the full year, as substantially all SOL holdings were staked throughout the periodRaised $29.9 million in 2025 through the Company's ATM programs, with proceeds used primarily to purchase SOL on an net asse

    3/30/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026

    NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its fourth quarter and full year operating results on Monday, March 30, 2026, after market close. Management will host a conference call to discuss the results and provide an expanded business update as follows: Date:Monday, March 30, 2026Time:4:30 p.m. Eastern TimeWebcast:Click hereParticipant call link:Click here (register to receive unique PIN and dial-in number)   The webcast will be archived unde

    3/24/26 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Solana Company Reports Third Quarter 2025 Financial Results

    NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ:HSDT) (the "Company" or "HSDT"), a publicly listed company that has expanded its business to include a digital asset treasury ("DAT") dedicated to acquiring and holding Solana tokens ("SOL"), today announced results for the quarter ended September 30, 2025. Third Quarter and Recent Business Updates Closed partnership with Pantera Capital and Summer Capital of over $500 Million in funding in cash and stablecoins to launch SOL treasury strategyIssued cash-exercise warrants, allowing for a potential aggregate $750M additional capital raise for the CompanyLaunched ATM program, giving the company flexibility to raise addi

    11/18/25 4:05:00 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care